Cancer

[키워드] 1:1 95% CI absence addition administration of hydroxychloroquine Admission aerosol-generating procedures allergy analyzed Anesthesia antibody approved ARMS assigned balanced randomization blind Cancer Cantabria carried CDC Cell Chemoprophylaxis clinical Clinical data clinically coated Committee comparator Comparator group computer-generated control group Controlled Controlled clinical trial Controlled trial coronavirus COVID COVID-19 criteria CURB current detect Determination disease dissemination double blind double-blind dropout rate Efficacy Efficacy and safety element ELISA kit Emergency Endocrine estimate Ethics Euroimmun Evidence evidence of Germany GRADE greater group Health Health authority health-care healthcare personnel Healthcare professional healthcare professionals heart heart failure help hematological high risk hospital Hydroxychloroquine hydroxychloroquine sulfate hygiene Hypothesis ICU IDT IgA IgG IgM and IgG immune immunodeficiency in vitro incidence include Infection inhibit intensive care unit Intervention investigator kidney lactation liver measure Measures Medicine Negative PCR neurological New York number observation period outcome participant PCR performed Personal protective equipment Placebo positive positive SARS-CoV-2 PCR positive serology Pregnancy presenting Prevalence Primary outcome probes product professional Prophylaxis Prospective PROTECT Protective protocol Psychiatric randomised randomised controlled trial randomization Randomized randomized trial RCT receive recruitment reduce reported responsible risk RT-PCR Sample size SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 PCR sequence Seroconversion serological serology severity Significant single center single-center study social distancing Spain Spanish Standard Statistical power status Study protocol subject Support Symptom symptomatic and asymptomatic Tablet Takara Taking Tamoxifen Transmission Treatment two-tailed university Vaccine virus website while
[DOI] 10.1186/s13063-020-04400-4 PMC 바로가기 [Article Type] Letter